Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Vista sencilla de ítem
dc.contributor.authorMachado, Pedro M.
dc.contributor.authorSchäfer, Martin
dc.contributor.authorMahil, Satveer K
dc.contributor.authorLiew, Jean
dc.contributor.authorGossec, Laure
dc.contributor.authorDand, Nick
dc.contributor.authorPfeil, Alexander
dc.contributor.authorStrangfeld, Anja
dc.contributor.authorRegierer, Anne Constanze
dc.contributor.authorFautrel, Bruno
dc.contributor.authorAlonso, Carla Gimena
dc.contributor.authorSaad, Carla G. S.
dc.contributor.authorGriffiths, Christopher E. M.
dc.contributor.authorLomater, Claudia
dc.contributor.authorMiceli Richard, Corinne
dc.contributor.authorWendling, Daniel
dc.contributor.authorAlpizar Rodriguez, Deshire
dc.contributor.authorWiek, Dieter
dc.contributor.authorMateus, Elsa F.
dc.contributor.authorSirotich, Emily
dc.contributor.authorSoriano, Enrique R.
dc.contributor.authorRibeiro, Francinne Machado
dc.contributor.authorOmura, Felipe
dc.contributor.authorRajão Martins, Frederico
dc.contributor.authorSantos, Helena
dc.contributor.authorDau, Jonathan
dc.contributor.authorBarker, Jonathan N.
dc.contributor.authorHausmann, Jonathan
dc.contributor.authorHyrich, Kimme L.
dc.contributor.authorSilva, Ligia
dc.contributor.authorJacobsohn, Lindsay
dc.contributor.authorCarmona, Loreto
dc.contributor.authorPinheiro, Marcelo M.
dc.contributor.authorZelaya, Marcos David
dc.contributor.authorSeverina, María de los Ángeles
dc.contributor.authorYates, Mark
dc.contributor.authorDubreuil, Maureen
dc.contributor.authorGore Massy, Monique
dc.contributor.authorRomeo, Nicoletta
dc.contributor.authorHaroon, Nigil
dc.contributor.authorSufka, Paul
dc.contributor.authorGrainger, Rebecca
dc.contributor.authorHasseli, Rebecca
dc.contributor.authorLawson Tovey, Saskia
dc.contributor.authorBhana, Suleman
dc.contributor.authorPham, Thao
dc.contributor.authorOlofsson, Tor
dc.contributor.authorBautista Molano, Wilson
dc.contributor.authorWallace, Zachary S.
dc.contributor.authorYiu, Zenas Z. N.
dc.contributor.authorYazdany, Jinoos
dc.contributor.authorRobinson, Philip C.
dc.contributor.authorSmith, Catherine H.
dc.contributor.orcidMachado, Pedro M. [0000-0002-8411-7972]
dc.contributor.orcidSchäfer, Martin [0000-0001-6487-3634]
dc.contributor.orcidGossec, Laure 0000-0002-4528-310X
dc.contributor.orcidPfeil, Alexander [0000-0002-2709-6685]
dc.contributor.orcidStrangfeld, Anja [0000-0002-6233-022X]
dc.contributor.orcidRegierer, Anne Constanze [0000-0003-2456-4049]
dc.contributor.orcidFautrel, Bruno [0000-0001-8845-4274]
dc.contributor.orcidMiceli Richard, Corinne [0000-0002-3009-3637]
dc.contributor.orcidWendling, Daniel [0000-0002-4687-5780]
dc.contributor.orcidAlpizar Rodriguez, Deshire [0000-0002-6930-0517]
dc.contributor.orcidMateus, Elsa F. [0000-0003-0059-2141]
dc.contributor.orcidSirotich, Emily [0000-0002-7087-8543]
dc.contributor.orcidSoriano, Enrique R. [0000-0003-3143-1084]
dc.contributor.orcidRibeiro, Francinne Machado [0000-0003-0038-983X]
dc.contributor.orcidRajão Martins, Frederico [0000-0002-9742-2677]
dc.contributor.orcidHausmann, Jonathan [0000-0003-0786-8788]
dc.contributor.orcidHyrich, Kimme L. [0000-0001-8242-9262]
dc.contributor.orcidGensler, Lianne
dc.contributor.orcidCarmona, Loreto [0000-0002-4401-2551]
dc.contributor.orcidPinheiro, Marcelo M. [0000-0002-1896-8322]
dc.contributor.orcidYates, Mark [0000-0001-5449-5211]
dc.contributor.orcidHasseli, Rebecca [0000-0002-2982-8253]
dc.contributor.orcidLawson Tovey, Saskia [0000-0002-8611-162X]
dc.contributor.orcidPham, Thao [0000-0002-5978-0983]
dc.contributor.orcidOlofsson, Tor [0000-0002-9919-4487]
dc.contributor.orcidRobinson, Philip C. [0000-0002-3156-3418]
dc.contributor.orcidSmith, Catherine H.
dc.date.accessioned2023-05-02T13:26:26Z
dc.date.available2023-05-02T13:26:26Z
dc.date.issued2023
dc.description.abstractOBJETIVOS: Investigar los factores asociados con la gravedad de la COVID-19 en personas con psoriasis (PsO), artritis psoriásica (PsA) y espondiloartritis axial (axSpA). MÉTODOS: Se obtuvieron datos demográficos, características clínicas y gravedad de la COVID-19 de adultos con PsO, PsA y axSpA de dos registros internacionales notificados por médicos. Se definió una escala ordinal de gravedad COVID-19 de tres puntos: ninguna hospitalización, hospitalización (y ninguna muerte) y muerte. Las OR se estimaron mediante regresión logística ordinal multivariable. RESULTADOS: De 5045 casos, el 18,3% tenía PsO, el 45,5% PsA y el 36,3% axSpA. La mayoría (83,6%) no fueron hospitalizados, el 14,6% fueron hospitalizados y el 1,8% fallecieron. La edad avanzada se asoció de forma no lineal con la gravedad de la COVID-19. El sexo masculino (OR 1,54; IC del 95%: 1,30 a 1,83), las comorbilidades cardiovasculares, respiratorias, renales, metabólicas y oncológicas (OR 1,25-2,89), la actividad moderada/alta de la enfermedad y/o el uso de glucocorticoides (OR 1,39-2,23, frente a remisión/baja actividad de la enfermedad y ausencia de glucocorticoides) se asociaron con mayores probabilidades de COVID-19 grave. Los periodos de pandemia más tardíos (ORs 0,42-0,52, vs hasta el 15 de junio de 2020), la PsO (OR 0,49, IC 95% 0,37 a 0,65, vs PsA) y la exposición basal a TNFi, IL17i e IL-23i/IL-12+23i (OR 0,57, IC 95% 0. 44 a 0,73; OR 0,62; IC del 95%: 0,45 a 0,87; OR 0,67; IC del 95%: 0,45 a 0,98; respectivamente; frente a ningún fármaco antirreumático modificador de la enfermedad) se asociaron con una reducción de las probabilidades de COVID-19 grave. CONCLUSIÓN: La mayor edad, el sexo masculino, la carga de comorbilidad, la mayor actividad de la enfermedad y la ingesta de glucocorticoides se asociaron con una COVID-19 más grave. Los periodos pandémicos más tardíos, la PsO y la exposición a TNFi, IL17i e IL-23i/IL-12+23i se asociaron con una COVID-19 menos grave. Estos hallazgos permitirán la estratificación del riesgo e informarán las decisiones de gestión para pacientes con PsO, PsA y axSpA durante las oleadas de COVID-19 o pandemias respiratorias futuras similares.spa
dc.description.abstractenglishOBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1136/ard-2022-223499
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1468-2060
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/10341
dc.language.isoeng
dc.publisherBMJ Publishing Groupspa
dc.publisher.journalAnnals of the rheumatic diseasesspa
dc.relation.ispartofseriesAnnals of the rheumatic diseases, 1468-2060, 82, 5, May 2023, 698 - 709spa
dc.relation.urihttps://ard.bmj.com/content/82/5/698
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectArtritisspa
dc.subjectArtritis psoriásicaspa
dc.subjectAutoinmunidadspa
dc.subjectCovid-19spa
dc.subjectEspondilitisspa
dc.subjectAnquilosantespa
dc.subject.keywordsArthritisspa
dc.subject.keywordsArthritis Psoriaticspa
dc.subject.keywordsAutoimmunityspa
dc.subject.keywordsCovid-19spa
dc.subject.keywordsSpondylitisspa
dc.subject.keywordsAnkylosingspa
dc.titleCharacteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registriesspa
dc.title.translatedCaracterísticas asociadas a los malos resultados de COVID-19 en personas con psoriasis, artritis psoriásica y espondiloartritis axial: datos de los registros COVID-19 PsoProtect y Global Rheumatology Alliance notificados por médicos.spa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.coarversionhttps://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Characteristics associated with poor COVID 19 outcomes in people with psoriasis.pdf
Tamaño:
1.94 MB
Formato:
Adobe Portable Document Format
Descripción:
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registrie
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.95 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos